Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Abirateron

Classification: B

Drug products: ZYTIGA

ATC code: L02BX03

Substances: abiraterone, abiraterone acetate

Summary

As the substance is only used by men, analyses on sex or gender differences have not been considered relevant.

Additional information

Abiraterone is an inhibitor of 17 alpha-hydroxylase/C17,20-lyase (CYP17) that blocks androgen biosynthesis [1]. The approved indication for abiraterone in combination with methylprednisolone or prednisone is treatment of certain types of prostate cancer [2].

Updated: 2018-12-17

Date of litterature search: 2018-12-06

References

  1. Physicians' Desk Reference. http://www.pdr.net. [cited 2018-12-06]. länk
  2. Fass.se [cited 2018-12-06]. länk
  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-06.] länk

Authors: Mia von Euler

Reviewed by: Karin Schenck-Gustafsson

Approved by: Karin Schenck-Gustafsson